Congenital amegakaryocytic thrombocytopenia is an extremely rare disorder for which bone marrow transplantation offers the only possibility for cure. The pathophysiology is unclear. Two children with familial amegakaryocytic thrombocytopenia underwent unrelated donor transplantation (bone marrow in one, umbilical cord blood in the second) after a preparative regimen of cyclophosphamide and total body irradiation. Both patients failed initial engraftment, required further donor stem cell infusions and are currently well with sustained engraftment, 16 months and 7 months after transplantation, respectively. The difficulty in achieving engraftment of unrelated donor stem cells in these children suggests that in future cases additional measures to achieve engraftment may be necessary, for example, a more aggressive preparative regimen or an increased stem cell dose.
Familial amegakaryocytic thrombocytopenia is a rare constitutional marrow failure syndrome characterized by severe thrombocytopenia due to absent or markedly reduced numbers of megakaryocytes in the bone marrow, frequently with onset in the first year of life. 1 Affected patients generally have no associated physical anomalies. Approximately half of these patients eventually develop aplastic anemia and the median survival is 6 years. Autosomal recessive and X-linked forms have been described. 1, 2 A number of treatment regimens, including steroids, androgens, lithium carbonate, gammaglobulin, cyclosporine and splenectomy have met with limited success. The only long-term survivors have been recipients of BMT. 1, [3] [4] [5] In this report, we present two children with familial amegakaryocytic thrombocytopenia who experienced difficulty with engraftment of unrelated donor stem cells. Possible approaches to improve engraftment in this group of patients are discussed.
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Case reports

Patient 1
Patient 1 presented at birth with thrombocytopenia (platelet count of 17 ϫ 10 9 /l) for which he received a maternal platelet transfusion. Physical examination was normal with no dysmorphic features, hand or arm abnormalities, or nail dysplasias. Two weeks later his platelet count was 8 ϫ 10 9 /l with a hemoglobin of 12.3 g/dl, MCV 107 fl, WBC 7.1 ϫ 10 9 /l with an ANC of 1.1 ϫ 10 9 /l. Bone marrow aspiration and biopsy revealed amegakaryocytic thrombocytopenia. His older brother presented with the same condition at the age of 7 months, subsequently developed aplastic anemia over the course of his first year of life, and died of complications of aplasia at 3. years of age.
Patient 1 was treated with separate trials of IL-2, PIXY and IL-11 at other institutions, with some success. However, by the age of 3 years 8 months, he had become refractory to these medications and was referred to the University of Minnesota for transplantation. Assessment prior to BMT revealed a hemoglobin of 8 g/dl, platelet count of less than 10 ϫ 10 9 /l and an ANC between 0.4 and 0.7 ϫ 10 9 /l. The bone marrow biopsy showed an extremely hypocellular specimen with less than 5% cellularity. Cytogenetics and chromosomal breakage studies with mitomycin C and diepoxybutane (DEB) were normal. HLA typing was performed by serology for class I antigens and by high resolution molecular typing for class II antigens. /kg CD34 ϩ cells), after a conditioning regimen of cyclophosphamide 60 mg/kg/day for 2 days, and 1320 cGy TBI in 8 fractions. GVHD prophylaxis was short-course methotrexate and cyclosporin A; the marrow was not T cell depleted. Initially, engraftment was adequate with a day ϩ21 bone marrow aspirate demonstrating trilineage engraftment with 90-99% donor cells by DNA analysis (ANC 0.5 ϫ 10 9 /l was achieved by day ϩ33). Shortly thereafter, his ANC declined and treatment with G-CSF was started on day ϩ37. A bone marrow biopsy on day ϩ41 revealed mixed chimerism with 26-50% donor cells. Antithymocyte globulin (ATG) and cyclosporin A were administered; however, engraftment was not sustained. An infusion of 13.6 ϫ 10 8 nucleated cells/kg (5.17 ϫ 10 6 /kg CD34 ϩ ) mobilized peripheral blood stem cells from the same unrelated donor was given 57 days after the initial transplant, after administration of cyclophosphamide 50 mg/kg/day for 2 days. G-CSF and GM-CSF were administered daily. Prophylaxis for acute GVHD consisted of ATG, methylprednisolone and cyclosporin A. Twelve days after the second infusion of stem cells, engraftment was evident with a WBC of 1.9 ϫ 10 9 /l and ANC of 1.7 ϫ 10 9 /l. The subsequent clinical course was complicated by grade I skin GVHD, hemorrhagic cystitis, three episodes of E. coli sepsis and hypertension. He was discharged home 97 days after the second infusion in stable condition. He continues to show evidence of full donor chimerism with normal peripheral blood counts 16 months after his second transplantation and is functioning normally with a Lansky score of 100%.
Patient 2
Patient 2 was a 6-year-old boy who presented with a history of easy bruising and progressive thrombocytopenia. Fifteen months earlier, during a preoperative assessment for PE tube placement and adenoidectomy, a platelet count of 96 ϫ 10 9 /l was noted. Further investigations at presentation revealed a hemoglobin of 11.1 g/dl, mean corpuscular volume of 101 fl, platelet count of 32 ϫ 10 9 /l and WBC count of 6.0 ϫ 10 9 /l with a normal differential. Bone marrow examination revealed 40-50% cellularity, a markedly decreased number of megakaryocytes, and no evidence of dysplasia. His platelet count gradually declined over the next 5 months at which time he was referred to the University of Minnesota for transplantation. HLA typing was performed by serology for class I antigens and by high resolution molecular typing for class II antigens.
The family history was significant for a paternal third cousin who received a bone marrow transplant in December 1988 for aplastic anemia at the age of 26 years. This patient had markedly delayed hematopoietic recovery but subsequently died 2. years later from GVHD. Additionally, this cousin's maternal uncle (patient 2's second cousin) died at the age of 12 years in 1956, also with aplastic anemia. The father of patient 2 had a normal platelet count but with a slightly reduced mean platelet volume (MPV) of 6.2 fl. His younger sister had a marginally reduced platelet count of 180 000, a slightly reduced MPV of 6.3 fl and bone marrow examination showed 50% cellularity.
Physical examination of Patient 2 was normal with no dysmorphic features, hand or arm abnormalities or nail dysplasias present. Direct Coombs was negative and reticulocyte count 1%. A bone marrow aspiration and biopsy prior to transplant showed less than 5% cellularity, no megakaryocytes present, and no evidence of dysplasia. Cytogenetics were normal. Chromosomal breakage studies with mitomycin C and DEB were normal. Testing for platelet-associated antibodies was negative. Hemoglobin F was 3.7%. PNH testing was negative. HLA typing was performed by serology for class I antigens and by high resolution molecular typing for class II antigens.
At the age of 6 years, 8 /kg CD 34 ϩ cells) harvested from his HLA-identical sister. She had not been selected as the original donor as she had a slightly reduced platelet count and mean platelet volume with a relatively hypocellular marrow. As there was clinical urgency in achieving hematopoietic recovery, she was used as the donor, despite the possible diagnosis of amegakaryocytic thrombocytopenia in this child as well. Engraftment did not occur and 30 days later the bone marrow remained aplastic. During this time, the patient developed hemolytic streptococcal meningitis requiring a ventriculostomy and later a ventriculoperitoneal shunt for hydrocephalus. A second unrelated donor umbilical cord blood unit matched at HLA A and B, with a serological mismatch at a single DR locus which had become available in the bank during the course of the first transplant, was infused after a preparative regimen of cyclophosphamide, 50 mg/kg/day for 3 days, ATG and methylprednisone. This graft contained 0.48 ϫ 10 8 nucleated cells/kg (5.60 ϫ 10 5 /kg CD 34 ϩ cells). ANC Ͼ0.5 ϫ 10 9 /l was achieved 40 days after infusion of the second cord blood unit with 100% donor cells from the second cord blood unit verified on day ϩ56. His subsequent course was complicated by grade II skin and grade I gut GVHD, hemorrhagic cystitis and hypertension. He was discharged home 97 days after infusion of the second cord blood unit in stable condition and continues to show complete donor engraftment 7 months after his third stem cell transplantation. Except for some fatigue with excessive activity, he has returned to normal functioning, with a Lansky score of 80%.
Discussion
Congenital amegakaryocytic thrombocytopenia is an extremely rare disorder with only 24 reported cases in the literature. [1] [2] [3] [4] [5] [6] [7] Approximately half of these patients develop aplastic anemia with a median survival of 6 years. 1 The pathophysiology of this disorder is unclear with evidence supporting both an intrinsic stem cell disorder 3 and an inherent stromal defect. 6, 7 The pathogenesis of amegakaryocytic thrombocytopenia is unclear and is likely multifactorial. Serial clonogenic assays of marrow precursors in an infant with amegakaryocytic thrombocytopenia have shown a decline in precursors in parallel with the development of aplastic anemia, suggesting an intrinsic stem cell disorder. 3 On the other hand, generation of megakaryocyte colonies (CFU-MK) has been shown to improve after addition of IL-3 and GM-CSF in vitro and IL-3 administration improved platelet counts and decreased bleeding and transfusion requirements in vivo, suggesting an inherent stromal defect. 6 Stem cell factor has also been shown to increase erythroid progenitor production providing further evidence for a stromal abnormality. 7 The difficulty with engraftment seen in the two patients described in this report may reflect the presence of abnormalities of both stem cells and stroma in these patients.
The two patients in this report received the standard preparative regimen given to unrelated donor transplant recipients for aplastic anemia at this institution, but neither achieved satisfactory engraftment. There are two reported series of unrelated donor marrow transplantation in children and adolescents with aplastic anemia. 8, 9 In the Milwaukee series, three of 28 transplanted patients failed to engraft. In the Minnesota study, stable engraftment was achieved in all seven patients transplanted, although one patient had primary graft failure and required three infusions of marrow from two different unrelated donors to achieve stable donor hematopoiesis. Increased difficulty in engrafting HLA-disparate marrow has been noted by a number of authors. 10, 11 The frequency of graft failure is increased even in recipients of phenotypically well matched unrelated donor marrow when compared with recipients of sibling donor marrow, and is increased further in recipients of one antigen disparate marrow (eg Patient 2). In this report of familial amegakaryocytic thrombocytopenia, the histoincompatibility of the stem cells may have contributed to the difficult engraftment in both cases. There was no evidence of viral infections (although HHV-6 was not tested) or immunological rejection in either patient to explain engraftment failure.
One potential approach to facilitate engraftment in future cases would be the use of a larger initial cell dose. One reported case of unrelated donor BMT for amegakaryocytic thrombocytopenia received 5.7 ϫ 10 8 nucleated cells/kg and achieved good engraftment. 5 While this is feasible with bone marrow donors, cell dose is clearly limited when umbilical cord blood is used for transplantation. In future cases, careful consideration of cell dose should be made when umbilical cord blood transplantation is a possibility.
In patients with familial amegakaryocytic thrombocytopenia, bone marrow transplantation offers the only possibility for long-term survival. Although a more aggressive preparative regimen may be useful to obtain sustained engraftment, further studies of the effect of an increased stem cell dose are first warranted as they may prove effective and eliminate the need for more intensive conditioning with its associated undesirable side-effects.
